Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less.
暂无分享,去创建一个
J. Szer | D. Stroncek | J. Liesveld | Z. DeFilipp | B. Shaw | G. Switzer | H. Lazarus | B. Logan | M. Pulsipher | P. Hematti | C. Bredeson | M. Díaz | D. Confer | I. Ahmed | B. Savani | R. Olsson | S. Seo | P. Anderlini | N. Shah | M. Seftel | J. Halter | G. Hale | K. Kasow | H. Abdel-Azim | A. Beitinjaneh | S. Ganguly | J. Yared | D. Maharaj | D. Kiefer | P. Chitphakdithai | P. O'Donnell | Pashna N. Munshi | Zheng Zhou
[1] J. Tisdale,et al. Hematopoietic Progenitor Cell Mobilization is More Robust in Healthy African American Compared to Caucasian Donors , 2014 .
[2] J. Wingard,et al. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[3] B. Shaw,et al. Lower risk for serious adverse events and no increased risk for cancer after PBSC vs BM donation. , 2014, Blood.
[4] J. Wingard,et al. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. , 2013, Blood.
[5] J. Klein,et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. , 2009, Blood.
[6] T. Price,et al. Recovery and safety profiles of marrow and PBSC donors: experience of the National Marrow Donor Program. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[7] R. Hartzman,et al. Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[8] G. Ehninger,et al. Second donation of granulocyte–colony‐stimulating factor–mobilized peripheral blood progenitor cells: risk factors associated with a low yield of CD34+ cells , 2005, Transfusion.
[9] T. Panzarella,et al. An evaluation of the donor experience in the canadian multicenter randomized trial of bone marrow versus peripheral blood allografting. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] N. Schmitz,et al. Differences between graft product and donor side effects following bone marrow or stem cell donation , 2003, Bone Marrow Transplantation.
[11] C. Scheid,et al. Filgrastim mobilization and collection of allogeneic blood progenitor cells from adult family donors: first interim report of a prospective German multicenter study , 2002, Annals of Hematology.
[12] A. Gratwohl,et al. Repeated peripheral stem cell mobilization in healthy donors: time‐dependent changes in mobilization efficiency , 1999, British journal of haematology.
[13] P. Anderlini,et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience , 1999, Transfusion.
[14] Y. Kodera,et al. Peripheral blood stem cell mobilization and apheresis: analysis of adverse events in 94 normal donors , 1999, Bone Marrow Transplantation.
[15] G. Ehninger,et al. Acceptance and feasibility of peripheral stem cell mobilisation compared to bone marrow collection from healthy unrelated donors. , 1998, Bone marrow transplantation.
[16] D. Stroncek,et al. Blood counts in healthy donors 1 year after the collection of granulocyte–colony‐stimulating factor‐mobilized progenitor cells and the results of a second mobilization and collection , 1997, Transfusion.
[17] R. Champlin,et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections , 1997, British journal of haematology.
[18] D. Stroncek,et al. Treatment of normal individuals with granulocyte‐colony‐stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells , 1996, Transfusion.
[19] P. Anderlini,et al. Transient neutropenia in normal donors after G‐CSF mobilization and stem cell apheresis , 1996, British journal of haematology.
[20] D. Stroncek,et al. Changes in blood counts after the administration of granulocyte‐colony‐ stimulating factor and the collection of peripheral blood stem cells from healthy donors , 1996, Transfusion.
[21] R. Champlin,et al. Clinical toxicity and laboratory effects of granulocyte‐colony‐ stimulating factor (filgrastim) mobilization and blood stem cell apheresis from normal donors, and analysis of charges for the procedures , 1996, Transfusion.